Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease?

摘要

Patients with atherosclerosis of the small coronary arteries (small-vessel disease) are at high risk of restenosis after percutaneous coronary intervention (PCI). The SIRTAX investigators hypothesized that the subgroup of patients with small-vessel disease would derive the greatest benefit from drug-eluting stents (DESs), which are known to reduce late luminal loss.